All In Biotech

Drug Trial Radar · NCT05882357

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

A Phase 3, Open-label Study Evaluating the Pharmacokinetics, Safety, and Tolerability of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 12 to Less Than 24 Months of Age

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

67

Actual

Start

Jun 27, 2023

Primary completion

Sep 4, 2025

Study completion Sep 4, 2025

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
May 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 24 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study evaluates the pharmacokinetics (PK), safety, tolerability, pharmacodynamics (PD), and efficacy of ELX/TEZ/IVA in CF participants 2 to less than (\<) 24 months of age.

Conditions

  • Cystic Fibrosis

Interventions

  • ELX/TEZ/IVADrug

    Fixed-dose combination granules for oral administration.

  • IVADrug

    Granules for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and Their Relevant Metabolites (M23-ELX, M1-TEX, M1-IVA)Time frame: At Day 15
  2. Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Day 43
  3. Part B : Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Week 28

Locations

19 sites in 7 countries. Site status is shown where the registry gives one.

  • Telethon Kids Institute

    Nedlands, Australia

  • The Royal Children's Hospital

    Parkville, Australia

  • Queensland Children's Hospital

    South Brisbane, Australia

  • The Children's Hospital at Westmead

    Westmead, Australia

  • The Hospital for Sick Children

    Toronto, Canada

  • British Columbia Children's Hospital

    Vancouver, Canada

  • Juliane Marie Center, Rigshospitalet

    Copenhagen, Denmark

  • Charite Paediatric Pulmonology Department

    Berlin, Germany

  • Kinderklinik III, Abt. fur Pneumologie

    Essen, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Erasmus Medical Center / Sophia Children's Hospital

    Rotterdam, Netherlands

  • Inselspital - Universitaetsspital Bern

    Bern, Switzerland

  • Kinderspital Zuerich

    Zurich, Switzerland

  • Children and Young Adults Research Unit

    Cardiff, United Kingdom

  • Leeds General Infirmary

    Leeds, United Kingdom

  • Alder Hey Children's NHS Foundation Trust

    Liverpool, United Kingdom

  • Great Ormond Street Hospital for Children

    London, United Kingdom

  • Royal Brompton Hospital

    London, United Kingdom

  • Southampton General Hospital

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.